A review of deubiquitinases and thier roles in tumorigenesis and development

Frontiers in Bioengineering and Biotechnology

Bioengineering and Biotechnology

Bing Liu¹  Hui Liu¹  Sheng-Zhong Wang¹  Zhi Cao²  Xian-Wen Liang²  Feng-Ran Chu²  Jia-Cheng Chen²  Jin-Cai Wu²  Xiong Lin² 

[1] Department of Gastrointestinal Surgery, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China;Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China;

关键词: deubiquitinase;    deubiquitination;    tumor treatment;    deubiquitinase inhibitor;    cancer;   

DOI  :  10.3389/fbioe.2023.1204472

 received in 2023-04-12, accepted in 2023-05-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

Ubiquitin is a small protein that can be added onto target protein for inducing target degradation, thereby modulating the activity and stability of protein. Relatively, deubiquitinases (DUBs), a class catalase that can remove ubiquitin from substrate protein, provide a positive regulation of the protein amount at transcription level, post-translational modification, protein interaction, etc. The reversible and dynamic ubiquitination-deubiquitination process plays an essential role in maintaining protein homeostasis, which is critical to almost all the biological processes. Therefore, the metabolic dysregulation of deubiquitinases often lead to serious consequences, including the growth and metastasis of tumors. Accordingly, deubiquitinases can be served as key drug targets for the treatment of tumors. The small molecule inhibitors targeting deubiquitinases has become one of the hot spots of anti-tumor drug research areas. This review concentrated on the function and mechanism of deubiquitinase system in the proliferation, apoptosis, metastasis and autophagy of tumor cells. The research status of small molecule inhibitors of specific deubiquitinases in tumor treatment is introduced, aiming to provide reference for the development of clinical targeted drugs.

【 授权许可】

Unknown   
Copyright © 2023 Liang, Wang, Liu, Chen, Cao, Chu, Lin, Liu and Wu.